In Re Glumetza Antitrust Litigation
Case Number:
3:19-cv-05822
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Arnold & Porter
- Baker & Hostetler
- Block & Leviton
- Brown Neri
- Buchanan Ingersoll
- Competition Law Partners
- Cravath Swaine
- Dechert LLP
- DiCello Levitt
- Dillingham & Murphy
- Gibson Dunn
- Hagens Berman
- Hangley Aronchick
- Hilliard & Shadowen
- Kenny Nachwalter
- Kirkland & Ellis
- Labaton Keller
- Lowenstein Sandler
- Lowey Dannenberg
- Orrick Herrington
- Rivero Mestre
- Schneider Wallace
- Sperling & Slater
- Tadler Law LLP
- Taus Cebulash
- Wilson Sonsini
- Winston & Strawn
- Wisner Baum
Companies
- Albertsons Cos. Inc.
- Assertio Holdings Inc.
- Bausch Health Cos. Inc.
- Bi-Lo
- Cardinal Health Inc.
- CVS Health Corp.
- Humana Inc.
- Hy-Vee
- LifeWallet
- Lupin Ltd.
- McKesson Corp.
- Rite Aid Corp.
- Salix Pharmaceuticals, Ltd.
- Santarus, Inc.
- Service Employees International Union
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- The Kroger Co.
- United Food & Commercial Workers International Union
Sectors & Industries:
-
May 28, 2020
Pharma Cos. Slam Cert. Bid In Diabetes Drug Price-Fixing Suit
A group of pharmaceutical companies, including Bausch Health Co., has urged a California federal judge not to certify a class of buyers claiming the companies violated federal antitrust law by blocking a generic version of the diabetes drug Glumetza from entering the market.
-
March 06, 2020
Assertio, Lupin, Bausch Must Face Buyers' Price-Fixing Suit
A California federal judge has refused to dismantle a lawsuit alleging Bausch Health Co. and other pharmaceutical companies violated federal antitrust law by blocking a generic version of diabetes drug Glumetza through a reverse pay-for-delay scheme, but trimmed indirect buyers' federal antitrust claims.
- ← Previous
- 1
- 2
- Next →